Destroy Cancer Cells Articles & Analysis: Older
25 news found
The USA boasts better cancer survival rates than most other developed countries. This was made possible due to a number of factors. In America, much attention is paid to medical equipment. Local oncology centers are equipped with the latest technology, actively use innovative technologies and new medicines. In addition, oncology in the United States involves extensive screening and more ...
Importantly, as demonstrated in the same studies, sCD80’s unique actions may involve both awakening and boosting the immune system to recognize and destroy tumor cells. Under the terms of the agreement, BriaCell gains the worldwide rights to develop and commercialize sCD80, while UMBC maintains ownership of the patents. ...
Ulrike Köhl, Professor of Immuno-Oncology, University of Leipzig, director of the Fraunhofer Institute for Cell Therapy and Immunology, Leipzig as well as director of the Institute of Cellular Therapeutics, Hannover Medical School, Germany, a leading expert in the development and manufacturing of cell and gene therapies in cancer with a ...
With this agreement, H.U.B will become the third clinical center in the world to implement NT's ground-breaking technology, enabling new therapeutic options for cancer patients. BNCT is an emerging, biologically-targeted form of radiotherapy that destroys tumor cells with minimal impact to surrounding healthy cells. It has the ...
With this agreement, H.U.B will become the third clinical center in the world to implement NT's ground-breaking technology, enabling new therapeutic options for cancer patients. BNCT is an emerging, biologically-targeted form of radiotherapy that destroys tumor cells with minimal impact to surrounding healthy cells. It has the ...
Moreover, AFM28 demonstrated the ability to destroy CD123-positive tumor cell lines and primary leukemic cells via antibody-dependent cell-mediated cytotoxicity (ADCC). ...
The expansion cohorts include patients with renal cell carcinoma (clear cell), non-small cell lung cancer (EFGR mutant), and colorectal cancer. ...
The most common and most lethal of these cancerous tumors are glioblastoma (GBM). What is Glioblastoma? Glioblastoma is a type of glioma, which is a brain tumor that begins in the star-shaped glial cells that surround and support nerve cells in the brain. ...
(Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:00 p.m. ...
AFM24 activates the innate immune system to kill cancer cells by binding to CD16A on innate immune cells and EGFR, a protein widely expressed on solid tumors. ...
(Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2022 Annual General Meeting of Shareholders (the “Annual Meeting”) will be held on June 22, 2022 at 09:00 a.m. ...
(Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2022 results and corporate update on Wednesday, June 1, 2022. ...
The analysis also showed activation of cytotoxic T cells in the periphery, and infiltration of T cells into the tumor bed, suggesting stimulation of anti-cancer immunity beyond the innate immune system and the possible engagement of the adaptive immune system. ...
The platform also has the potential to be used for drug delivery as antibody drug conjugates (ADCs), as chimeric antigen receptor (CAR) T cells or for redirected T cell killing. Furthermore, such high affinity anti-glycan mAbs also have the potential to be used for targeted imaging to distinguish malignant from healthy tissue during cancer ...
ByScancell
The Phase 1 trial is testing Scancell’s two clinical candidates, SCOV1 and SCOV2 (COVIDITY), which in preclinical models have induced high titre antibodies and potent T cells against both the S and N antigens, including responses that cross-react with the Delta and Omicron variants. ...
ByScancell
“Neutron’s work to expand the reach and potential of BNCT is aligned with Cosylab’s dedication to improving radiation therapy at the highest level and providing advanced cancer care to patients,” said Mark Pleško, CEO of Cosylab. “We believe that, in sharing our software expertise, we can immensely improve the utility and capability of this ...
About myvac® myvac® is a viral vector (MVA – Modified Vaccinia Ankara) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. myvac®-derived products are designed to stimulate the patient’s immune system, recognize and destroy tumors using the patient’s own cancer specific genetic ...
TLS’ Neutron Beam System enables a new treatment modality for patients diagnosed with the most aggressive and recurrent cancers such as gliomas, head and neck tumors, and melanomas, by delivering more precise, targeted radiation to cancer cells while sparing damage to surrounding healthy tissue. ...
When neutron radiation is applied, the boron atoms react to generate alpha particles that destroy cancer cells. Healthy cells without the boron are spared, resulting in less normal tissue damage. ...
Sherman Oaks, CA – March 17, 2021 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the Company has entered into a clinical research agreement with Rutgers, The State University of New Jersey, to fund a Phase I clinical study testing a TCR-based ...